MedlineMDLN.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Medline (MDLN.O) trades at a P/E of 68.00x, P/B of 4.09x, P/S of 1.58x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 84th percentile over the trailing 10Y window (vs. 84th percentile over 3Y); P/B sits at the 46th percentile over the trailing 10Y window (vs. 46th percentile over 3Y); P/S sits at the 23rd percentile over the trailing 10Y window (vs. 23rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 88th percentile within its industry and the 89th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.24%, ranking at the 77th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 38.6 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Medline operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: MDLN · MDLN
Want the full picture on whether Medline (MDLN.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 68.00 | ||||||
| P/B (MRQ) | 4.09 | ||||||
| P/S (TTM) | 1.58 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 4.24% |